C-Met: a Potential Therapeutic Target for Hepatocellular Carcinoma

C-Met: a Potential Therapeutic Target for Hepatocellular Carcinoma

ISSN 1881-7831 Online ISSN 1881-784X DD&T Drug Discoveries & Therapeutics Volume 5 ● Number 1 ● 2011 www.ddtjournal.com ISSN: 1881-7831 Online ISSN: 1881-784X CODEN: DDTRBX Issues/Year: 6 Language: English Publisher: IACMHR Co., Ltd. Drug Discoveries & Therapeutics is one of a series of peer-reviewed journals of the International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) Group and is published bimonthly by the International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.) and supported by the IRCA-BSSA and Shandong University China-Japan Cooperation Center for Drug Discovery & Screening (SDU-DDSC). Drug Discoveries & Therapeutics publishes contributions in all fields of pharmaceutical and therapeutic research such as medicinal chemistry, pharmacology, pharmaceutical analysis, pharmaceutics, pharmaceutical administration, and experimental and clinical studies of effects, mechanisms, or uses of various treatments. Studies in drug-related fields such as biology, biochemistry, physiology, microbiology, and immunology are also within the scope of this journal. Drug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, News, and Letters on all aspects of the field of pharmaceutical research. All contributions should seek to promote international collaboration in pharmaceutical science. Editorial Board Editor-in-Chief: Masahiro MURAKAMI Osaka Ohtani University, Osaka, Japan Kazuhisa SEKIMIZU Yutaka ORIHARA The University of Tokyo, Tokyo, Japan The University of Tokyo, Tokyo, Japan Tomofumi SANTA Co-Editors-in-Chief: The University of Tokyo, Tokyo, Japan Wenfang XU Xishan HAO Shandong University, Ji'nan, China Tianjin Medical University, Tianjin, China Norihiro KOKUDO Web Editor: The University of Tokyo, Tokyo, Japan Yun YEN Yu CHEN City of Hope National Medical Center, Duarte, CA, USA The University of Tokyo, Tokyo, Japan Chief Director & Executive Editor: Proofreaders Wei TANG Curtis BENTLEY The University of Tokyo, Tokyo, Japan Roswell, GA, USA Thomas R. LEBON Managing Editor: Los Angeles, CA, USA Hiroshi HAMAMOTO The University of Tokyo, Tokyo, Japan Editorial Office Munehiro NAKATA Tokai University, Hiratsuka, Japan Pearl City Koishikawa 603, 2-4-5 Kasuga, Bunkyo-ku, Senior Editors: Tokyo 112-0003, Japan Tel: 03-5840-9697 Guanhua DU Fax: 03-5840-9698 Chinese Academy of Medical Science and Peking Union Medical E-mail: office@ddtjournal.com College, Beijing, China Xiao-Kang LI National Research Institute for Child Health and Development, Tokyo, Japan www.ddtjournal.com i Drug Discoveries & Therapeutics Editorial and Head Office Tel: 03-5840-9697, Fax: 03-5840-9698 Pearl City Koishikawa 603, 2-4-5 Kasuga, Bunkyo-ku, E-mail: office@ddtjournal.com Tokyo 112-0003, Japan URL: www.ddtjournal.com Editorial Board Members Alex ALMASAN Toshiaki KATADA Gary K. SCHWARTZ (Cleveland, OH) (Tokyo) (New York, NY) John K. BUOLAMWINI Gagan KAUSHAL Brahma N. SINGH (Memphis, TN) (Charleston, WV) (New York, NY) Shousong CAO Ibrahim S. KHATTAB Tianqiang SONG (Buffalo, NY) (Kuwait) (Tianjin) Jang-Yang CHANG Shiroh KISHIOKA Sanjay K. SRIVASTAVA (Tainan) (Wakayama, Wakayama) (Amarillo, TX) Fen-Er CHEN Robert Kam-Ming KO Hongbin SUN (Shanghai) (Hong Kong) (Nanjing, Jiangsu) Zhe-Sheng CHEN Nobuyuki KOBAYASHI Chandan M. THOMAS (Queens, NY) (Nagasaki, Nagasaki) (Bradenton, FL) Zilin CHEN Toshiro KONISHI Murat TURKOGLU (Wuhan, Hubei) (Tokyo) (Istanbul) Chandradhar DWIVEDI Minyong LI Fengshan WANG (Brookings, SD) (Ji'nan, Shandong) (Ji'nan, Shandong) Mohamed F. EL-MILIGI Jikai LIU Hui WANG (6th of October City) (Kunming, Yunnan) (Shanghai) Hao FANG Xinyong LIU Quanxing WANG (Ji'nan, Shandong) (Ji'nan, Shandong) (Shanghai) Marcus L. FORREST Yuxiu LIU Stephen G. WARD (Lawrence, KS) (Nanjing, Jiangsu) (Bath) Takeshi FUKUSHIMA Hongxiang LOU Bing YAN (Funabashi, Chiba) (Ji'nan, Shandong) (Ji'nan, Shandong) Harald HAMACHER Ken-ichi MAFUNE Yasuko YOKOTA (Tübingen, Baden-Württemberg) (Tokyo) (Tokyo) Kenji HAMASE Sridhar MANI Takako YOKOZAWA (Fukuoka, Fukuoka) (Bronx, NY) (Toyama, Toyama) Xiaojiang HAO Tohru MIZUSHIMA Rongmin YU (Kunming, Yunnan) (Tokyo) (Guangzhou, Guangdong) Waseem HASSAN Abdulla M. MOLOKHIA Guangxi ZHAI (Rio de Janeiro) (Alexandria) (Ji'nan, Shandong) Langchong HE Yoshinobu NAKANISHI Liangren ZHANG (Xi'an, Shaanxi) (Kanazawa, Ishikawa) (Beijing) Rodney J. Y. HO Xiao-Ming OU Lining ZHANG (Seattle, WA) (Jackson, MS) (Ji'nan, Shandong) Hsing-Pang HSIEH Weisan PAN Na ZHANG (Zhunan, Miaoli) (Shenyang, Liaoning) (Ji'nan, Shandong) Yongzhou HU Rakesh P. PATEL Ruiwen ZHANG (Hangzhou, Zhejiang) (Mehsana, Gujarat) (Amarillo, TX) Yu HUANG Shivanand P. PUTHLI Xiu-Mei ZHANG (Hong Kong) (Mumbai, Maharashtra) (Ji'nan, Shandong) Hans E. JUNGINGER Shafi qur RAHMAN Yongxiang ZHANG (Marburg, Hesse) (Brookings, SD) (Beijing) Amrit B. KARMARKAR Adel SAKR (Karad, Maharashra) (Cairo) (As of February 2011) ii www.ddtjournal.com CONTENTS Volume 5, Number 1, 2011 Editorial 1 Drug Discoveries & Therapeutics: A platform for promoting pharmaceutical sciences and clinical therapeutics. Yun Yen Review 2 - 11 c-Met: A potential therapeutic target for hepatocellular carcinoma. Jianjun Gao, Yoshinori Inagaki, Xia Xue, Xianjun Qu, Wei Tang Brief Report 12 - 17 Antibacterial activities of Sesbania grandiflora extracts. Pimporn Anantaworasakul, Srikanjana Klayraung, Siriporn Okonogi Original Articles 18 - 25 Purification of innate immunostimulant from green tea using a silkworm muscle contraction assay. Saphala Dhital, Hiroshi Hamamoto, Makoto Urai, Kenichi Ishii, Kazuhisa Sekimizu 26 - 31 Anti-influenza viral effects of novel nuclear export inhibitors from Valerianae Radix and Alpinia galanga. Ken Watanabe, Hanae Takatsuki, Megumi Sonoda, Satoru Tamura, Nobutoshi Murakami, Nobuyuki Kobayashi 32 - 40 A comparative study of protective mechanisms of glycine and L-arginine against cisplatin-induced nephrotoxicity in rat renal cortical slices. Yasmen YFK Mahran, Amani E Khalifa, Ebtehal El-Demerdash 41 - 52 Validated spectrophotometric methods for determination of some oral hypoglycemic drugs. Maha Farouk, Osama Abdel-Satar, Omar Abdel-Aziz, Maya Shaaban www.ddtjournal.com iii CONTENTS (Continued ) 53 - 59 Matrix type transdermal therapeutic systems of glibenclamide: Formulation, ex vivo and in vivo characterization. Asgar Ali, Anupam Trehan, Zabih Ullah, Mohammed Aqil, Yasmin Sultana Guide for Authors Copyright iv www.ddtjournal.com Drug Discoveries & Therapeutics. 2011; 5(1):1. 1 Editorial Drug Discoveries & Therapeutics: A platform for promoting pharmaceutical sciences and clinical therapeutics Yun Yen Co-Editor-in-Chief Drug Discoveries & Therapeutics Yun Yen, M.D., Ph.D. Professor and Chair of Molecular Pharmacology City of Hope Beckman Center Duarte, CA, USA In 2011, the world is filled with both challenges and opportunities across disciplines. Around the world, all look for opportunities to improve the economy by investing in eco-industry as well as biotechnology. Within biotechnology, drug discovery and therapeutics remain the mainstays of biomedical research. Drug discovery bridges the gap between pre-clinical research and clinical therapeutics to benefit human health. The three main tenets of drug discovery and therapeutics, molecular diagnostics, targeted therapy, and personalized medicine, will be our focuses as well in Drug Discoveries & Therapeutics in the present and near future. To do so, Drug Discoveries & Therapeutics must welcome new topics that align themselves with traditional areas of research in drug development and therapeutics. We must continue to emphasize topics on biomarker-guided therapies in proteomics, metabolomics, genomics, and genetics as well as up-and-coming areas of research such as autophagy, exosomes, and RNA spliceosomes. Research on small molecules, peptides, monoclonal antibodies, nano-particles, will and should be covered by this journal's scope alongside pharmacokinetics, pharmacodynamics, and drug delivery systems. The journal will continue to invite outstanding review articles, original research papers, and frontier discoveries, while simultaneously attracting a greater readership. Our immediate goal is to become a leading authority in the biomedical research field of drug discovery and therapeutics. Allongside editorial colleagues, I will continue to bring high quality, efficient publications to our readership. (February 5, 2011) www.ddtjournal.com 2 Drug Discoveries & Therapeutics. 2011; 5(1):2-11. Review DOI: 10.5582/ddt.2011.v5.1.2 c-Met: A potential therapeutic target for hepatocellular carcinoma Jianjun Gao1,2, Yoshinori Inagaki1, Xia Xue2, Xianjun Qu2, Wei Tang1,2,* 1 Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; 2 School of Pharmaceutical Sciences, Shandong University, Ji'nan, China. ABSTRACT: The approval of receptor tyrosine targeted therapies has opened new prospects in treatment kinase (RTK) targeted agent sorafenib as the first of HCC. Systemic treatment with sorafenib, a multikinase effective drug for the systemic treatment of advanced inhibitor targeting Raf kinase and receptor tyrosine hepatocellular carcinoma (HCC) represents a kinases (RTKs) including platelet-derived growth factor milestone in the treatment of this disease. A better receptor (PDGFR), vascular endothelial growth factor understanding of HCC pathogenesis will lead to (VEGF) receptor (VEGFR) and c-kit (receptor specific development of

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    70 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us